The Skinny Shot
Weight Loss Program
GLOW 365 now offers a Weight Loss Program under the administration of Nurse Practitioner Jill Crotty. The program features weekly injections of “The Skinny Shot” also known as Semaglutide, Wegovy, or Ozempic. Semaglutide is FDA-approved for weight loss and works by reducing hunger sensations. Our Semaglutide injections also include Vitamin B12 which helps with mood and increases energy. The GLOW 365 program includes initial consultation, all necessary lab work, medication and supplies, supplementation to aid in weight loss, nutritional information, and weight and measurement tracking. The program is appropriate for both men and women over the age of 18.
Begin your weight loss journey now.
Weight Loss Consultation
The initial Weight Loss Consultation is the first step in the GLOW 365 Weight Loss Program. You will meet with Nurse Practitioner Jill Crotty who will review your medical history and establish if you qualify for the program. Together, you will discuss your weight loss goals and your intial weight and measurements will be taken.
Lab work may be recommended to help us determine your current state of health and existing imbalances. Follow-up labs may be required as you progress along your weight loss journey.
The core feature of the GLOW 365 Weight Loss Program is once-weekly injections with Semaglutide or the “Skinny Shot”. Additionally, program participants receive supplementation to aid in weight loss goals, nutrition information, other weight loss tools, and a goodie bag upon enrollment.
Weight & Measurements Check
Once on the program, clients can schedule complimentary visits with any member of our nursing team to discuss progress, receive weight and body measurement checks, and review any questions.
Initial Consultation • $150
applied to your first month’s fee if approved
3-Month Program • $500 per month
covers all injections, lab work, and supplements
Weight & Measurement Checks • complimentary
can be scheduled as needed
Benefits of Semaglutide Weight Loss Injection
Start with a Weight Loss Consultation to determine if the program may be right for you.
Increases feeling of fullness
Improves insulin resistance
Lowers cholesterol and inflammation
Produces sustained weight loss
FDA approved for weight loss
Suitable for men and women
Includes Vitamin B12
Semaglutide Weight Loss FAQs
Your body naturally produces several substances that affect your appetite. One of these is called glucagon-like peptide-1 (GLP-1). The body produces GLP-1 naturally when you eat. GLP-1 stops you from feeling hungry and makes you feel full or satisfied. Semaglutide imitates GLP-1 in the body. This means that Semaglutide provides the same effect as this natural substance (GLP-1) in our bodies.
Semaglutide slows down stomach emptying so that after eating, you feel full longer. It also suppresses appetite and food cravings (on average patients eat ~30% less) and lowers blood glucose levels (without making glucose levels too low).
Because Semaglutide reduces feelings of hunger, you eat less food. When combined with a healthy diet and exercise, Semaglutide will help you lose weight.
Adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) and 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) may be a good candidate for Semaglutide injections.
Some individuals may not be a candidate for Semaglutide injections. If you have any of the following conditions, you cannot take Semaglutide:
- Personal or family history of Medullary Thyroid Carcinoma (MTC)
- Personal or family history of Multiple Endocrine Neoplasia, type 2 (MEN 2)
- Prior allergic reaction to Semaglutide or to any of its ingredients* (serious allergic reactions, including anaphylaxis and angioedema, have been reported with Semaglutide)
- Diabetic retinopathy (diabetic eye disease)
- Pregnant or trying to get pregnant (the estimated background risk of major birth defects is ~3% and the estimated background risk of miscarriage is ~18% – these percentages are increased with use of Semaglutide during pregnancy)
- Breast-feeding (Semaglutide is present in breast milk)
- Less than 18 years old
- Depression with a history of suicidal thoughts
Some individuals require special consideration. You might not be able to take Semaglutide if you have any of the following conditions:
- History of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting)
- Kidney disease/kidney insufficiency
- Stomach problems (Semaglutide will likely make these problems worse)
- Diabetes (must obtain approval for use from an endocrinologist or primary care physician)
It is recommended that individuals treated with Semaglutide engage in 20-30 minutes a day of walking or other exercises.
Up to 75% of patients have gastrointestinal side effects. These effects are generally mild-to-moderate in severity and are typically temporary. 95% of patients can continue using the medication despite these problems. The most common gastrointestinal side effects are nausea, vomiting, diarrhea, and constipation. The average duration of these symptoms:
- Nausea, 5 days
- Diarrhea, 3 days
- Vomiting, 2 days
- Constipation, 27 days
Semaglutide is administered by injection once a week. It stays in your system for 7-14 days after each injection. It reaches its maximum concentration in the body 1 to 3 days after a dose. If you experience side effects, they will likely be most pronounced during the 1-3 days after each dose.
Patients may also experience abdominal pain, headache, fatigue, indigestion, dizziness, abdominal distension, bloating, burping, flatulence (gas), and gastroesophageal reflux (heartburn).
Things to Consideration Prior to Weight Loss Treatment with Semaglutide:
- Females and Males of Reproductive Potential: Semaglutide can increase the risk of birth defects and miscarriage. Semaglutide must be discontinued at least 2 months before a planned pregnancy.
- Risk of Thyroid C-Cell Tumors: Contact your primary care physician if you develop symptoms of thyroid tumors (e.g., a mass in the neck, difficulty swallowing, difficulty breathing, persistent hoarseness). This has occurred in lab animals given Semaglutide.
- Pancreatitis: Acute and chronic pancreatitis have been reported in clinical studies. Notify your primary care physician if you have signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting). If pancreatitis is suspected, discontinue Semaglutide promptly. If pancreatitis is confirmed, you will no longer be able to take the medication. This occurs in less than 1% of patients taking Semaglutide.
- Diabetic retinopathy: Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy (vision problems).
- Hypoglycemia: Patients receiving Semaglutide in combination with insulin or a medication that increases insulin production (e.g., sulfonylurea) may have increased risk of hypoglycemia (low blood sugar), including severe hypoglycemia. Reducing the dose of insulin or other diabetes medications may be necessary while taking Semaglutide. You will need to tell the doctor that manages your diabetes that you are taking Semaglutide.
In a randomized clinical trial that included 611, either overweight or obese adults, individuals treated with Semaglutide for 68 weeks had the following results on average:
- Decreased body weight (on average, patients lose 26-34 lb. over 68 weeks)
- 70% of patients achieve at least 10% weight loss
- Over 50% achieve at least 15% weight loss
- One-third achieve at least 20% weight loss
- 3 ½ inch reduction in waist circumference
- 4.5 decrease in body-mass index
- 5 mmHg decrease in systolic BP
- Improved physical functioning
- Improved lipid profiles: decreased total cholesterol, VLDL, free fatty acids, and triglycerides
- Lowered fasting blood glucose level (Semaglutide improves blood glucose control in adults with type 2 diabetes and may be used with diabetes medicines)
- Lowered C-reactive protein (a marker of inflammation)
- Semaglutide reduces the risk of heart attack and stroke
Source: Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. Published in the Journal of American Medicine, February 2021.